YF-VAX 1 dose vials
Ended Awarded
- Contract number
- SPE2DR26FSBZ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $111,352
Award facts
- Contract value 100% obligated
- $111,352.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $111,352 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for YF-VAX (yellow fever vaccine) in single-dose vial format. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense. The contract award carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The delivery order is scheduled for completion by December 5, 2025, and represents one of numerous orders issued to the company within the PPV-G GEN V framework.
DMS Pharmaceutical Group's prime vendor agreement under PPV-G GEN V, designated contract SPE2DR and valued at $499,999,999 through December 31, 2036, positions the company as a critical supplier of pharmaceuticals and medical consumables to military healthcare facilities globally. The underlying IDC structure enables the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription medications, biologics, vaccines, and medical supplies to support Department of Defense healthcare operations. DMS Pharmaceutical Group's extensive product portfolio and demonstrated performance across multiple therapeutic categories have established the company as a capable regional prime vendor within the Defense Logistics Agency's pharmaceutical supply chain network.
Quick answers
Who was awarded contract SPE2DR26FSBZ4?
SPE2DR26FSBZ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FSBZ4 worth?
The government has obligated $111,352 on SPE2DR26FSBZ4.
Is contract SPE2DR26FSBZ4 an order under another contract?
Yes. SPE2DR26FSBZ4 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSBZ4 competed?
The extent of competition for SPE2DR26FSBZ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award